| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nav beta3 | ILX:0107321 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Nav beta4 | ILX:0107322 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Nav1.1 | ILX:0107323 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Nav1.2 | ILX:0107324 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Nav1.3 | ILX:0107325 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Nav1.4 | ILX:0107326 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Nav1.5 | ILX:0107327 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Nav1.6 | ILX:0107328 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Nav1.7 | ILX:0107329 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Nav1.8 | ILX:0107330 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Nav1.9 | ILX:0107331 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| Nax | ILX:0107332 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex | |
| NCIRE | Nonprofit research institute in the United States devoted to advancing Veterans health research. Along with their partners at the San Francisco VA Medical Center and the University of California, San Francisco, they:* Provide care for Veterans* Discover and develop effective, safe, and practical treatments for military injuries and diseases, and deploy them worldwide* Train new researchers in Veterans health* Prepare new generations of providers to care for Veterans in the years to comeThey focus on:* Psychological Health / Post-Traumatic Stress* Traumatic Brain Injury* Gulf War illness* Heart disease* Cancer* Alzheimer's and Parkinson's diseases* Chronic kidney and liver diseases* Readjustment and reintegration into society | ILX:0107333 | 4 | FDI Lab - SciCrunch.org | 08/24/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | troy sincomb |
| Necessary (continuant) | A necessity quality of continuant inhering in a bearer by virtue of being essential or indispensable. | ILX:0107334 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Necessary (occurent) | A necessity quality (occurent) inhering in a bearer by virtue of it being essential or indispensable. | ILX:0107335 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Necessity (continuant) | A monadic quality of continuant inhering in a bearer by virtue of whether it is essential or indispensable. | ILX:0107336 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Necessity of occurent | A monadic quality of occurent inhering in a bearer by virtue of whether it is essential or indispensable. | ILX:0107337 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Necrotic | A structural quality inhering in a bearer by virtue of the bearer's undergoing unprogrammed cell death. | ILX:0107338 | 4 | FDI Lab - SciCrunch.org | 08/24/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | troy sincomb |
| Nedocromil | A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets. (PubChem) Pharmacology: Nedocromil is a anti-inflammatory agent and can be administered directly to the bronchial mucosa. It has significant inhibitory effect on allergen-induced early and late asthmatic reactions and on bronchial hyperresponsiveness. Mechanism of action: Nedocromil has been shown to inhibit the in vitro activation of, and mediator release from, a variety of inflammatory cell types associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets. Nedocromil inhibits activation and release of inflammatory mediators such as histamine, prostaglandin D2 and leukotrienes c4 from different types of cells in the lumen and mucosa of the bronchial tree. These mediators are derived from arachidonic acid metabolism through the lipoxygenase and cyclo-oxygenase pathways. The mechanism of action of nedocromil may be due partly to inhibition of axon reflexes and release of sensory neuropeptides, such as substance P, neurokinin A, and calcitonin-generelated peptides. The result is inhibition of bradykinin-induced bronchoconstriction. Nedocromil does not posess any bronchodilator, antihistamine, or corticosteroid activity. Drug type: Approved. Small Molecule. Drug category: Anti-Allergic Agents. Anti-Asthmatic Agents. Anti-inflammatory Agents | ILX:0107339 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |
| Needle and Holder | The needleholder should grasp the needle firmly and not move when driven through the tissue. | ILX:0107340 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/09/2016 | 0 | NeuroLex | NeuroLex |